Greene, an architect of Alnylam, looks to the next chapter

Barry Greene, who has worked with CEO John Maraganore to build Alnylam for the past 17 years, will depart the RNAi company as president at the end of the quarter.

Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) said Greene is leaving to “pursue outside interests in the biopharmaceutical industry” but will consult for the company for as many as two years while it seeks a new chief commercial officer. Yvonne Greenstreet, a four-year veteran of Alnylam, will become president on Oct. 1 while remaining COO...